A Phase 1 interventional study of Experimental drug: ESK-001 and Placebo in Safety and Tolerability, sponsored by Alumis Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-05-09.
Sponsored by Alumis Inc · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Multiple Dose Study to Determine the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ESK-001 in Healthy Participants
This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.)
Alumis Inc is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 10 completed or terminated interventional studies of FDA-regulated products, 1 (10%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo for ESK-001
Other: Placebo
Experimental Drug ESK-001
Drug: Experimental drug: ESK-001
Multiple doses of ESK-001
Placebo
Incidence of Adverse Events (AEs)
Safety and tolerability
Time frame: Up to 14 days
Incidence of Serious Adverse Events (SAEs)
Safety and tolerability
Time frame: Up to 14 days
The area under plasma concentration-time curve from time zero extrapolated to last measurable concentration (AUCt) for ESK001 on Day 1 and Day 14
Pharmacokinetics
Time frame: Up to 14 days
The area under the plasma concentration-curve over the dosing interval (AUC(0-τ)) for ESK001 on Day1 and Day 14
Pharmacokinetics
Time frame: Up to 14 days
The observed maximum plasma concentration (Cmax) for ESK001 on Day 1 and Day 14.
Pharmacokinetics
Time frame: Up to 14 days
The time to reach the observed maximum plasma concentration (tmax) for ESK001 on Day 1 and Day 14.
Pharmacokinetics
Time frame: Up to 14 days
Apparent plasma elimination half-life (t½λz) for ESK001 on Day 1 and Day 14
Pharmacokinetics
Time frame: Up to 14 days
Apparent clearance CL(Clearance)/F for ESK001 on Day 1
Pharmacokinetics
Time frame: Up to 14 days
The accumulation ratio for AUC(0-τ) (RAC AUC(0-τ)) for ESK001 on Day 14
Pharmacokinetics
Time frame: Up to 14 days
The accumulation ratio for Cmax (RAC Cmax) for ESK001 on Day 14.
Pharmacokinetics
Time frame: Up to 14 days
Cytokine induction of pSTAT expression and downstream cytokine production as a measure of tyk2 pathway inhibition by ESK001
Pharmacodynamics
Time frame: 14 days after first dose
Ran from May 2022 to primary completion in Dec 2022, 6 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Envudeucitinib
Alumis Inc